Altor BioScience Awarded Two SBIR Phase I Grants by NCI for Research on its Novel IL-15 Super Agonists for Hematologic Cancers

Miramar, Florida, Sept. 27, 2012 -- Altor BioScience Corporation (Altor) announced today that it has been awarded two Small Business Innovation Research (SBIR) Phase I grants by the National Cancer Institute (NCI) to support research involving its interleukin-15 (IL-15) based superagonist complex, ALT-803, against multiple myeloma and B-cell lymphomas.

Altor was awarded the first grant of $231,853 in July 11, 2012, for the project entitled “IL-15 Superagonist Complex, known as ALT-803, as an Immunotherapeutic for Multiple Myeloma.” In this project, Altor is evaluating ALT-803 in preclinical models for hematologic cancers, including multiple myeloma. The preliminary data indicated that ALT-803 exhibited very potent anti-myeloma activity. The grant will allow Altor to explore the mechanism of action of ALT-803 and lay the ground work for clinical development.

The second grant of $257,303, awarded to Altor on September 2012 for the project entitled “CD20-targeted IL-15 immunotherapeutics for B-cell malignancies,” will provide the necessary resources to complete the ongoing evaluation of a targeted version of ALT-803 against B-cell lymphomas, including non-Hodgkin’s lymphoma, in relevant pre-clinical models. Derived from Altor’s proprietary IL-15 based protein scaffold technology, this novel immunotherapeutic is specifically targeted to the CD20 antigen, which is the target of Rituximab, an antibody therapeutic that is approved for treating B-cell lymphomas. Altor’s innovative CD-20 targeted immunotherapeutic has promising potential to deliver a significantly more potent drug than Rituximab for B-cell lymphomas.

Hing Wong, Ph.D., Altor's CEO commented, "Altor is extremely pleased to receive these SBIR awards from NCI and for the recognition of Altor’s novel and proprietary IL-15 based immunotherapeutic programs to address important unmet medical needs in the area of hematologic cancers. Altor’s top clinical priority is to move ALT-803 into clinical development in early 2013 and develop other targeted derivatives of ALT-803 to the clinical stage.”

About Altor’s IL-15 Technology

IL-15 is related to the approved immunotherapeutic, IL-2, and is a critical factor for the development, proliferation and activation of cellular immune responses. Altor has developed ALT-803, a novel IL-15 superagonist complex with enhanced biological activity in vitro and in vivo. ALT-803 is currently in late pre-clinical testing as a potential treatment for patients with superficial bladder cancer, other solid and hematological tumors.

About Altor BioScience

Altor is a privately held biotechnology company developing immunotherapies for treating cancer, viral infections, and inflammatory diseases based on its proprietary technology platforms. Altor currently has two products in clinical development. ALT-801 is Altor’s lead product based on its T-cell receptor (TCR) technology. This TCR-targeted immunotherapeutic for cancer is currently in Phase II trials to evaluate its safety and clinical utilities for treatment of patients with metastatic melanoma and for treatment of patients with advanced or metastatic urothelial cancer.

A monoclonal antibody-based Tissue Factor antagonist, referred to as ALT-836, is in a second multi-center, randomized Phase II trial for treatment of patients with Acute Respiratory Distress Syndrome and Acute Lung Injury, a life-threatening, systemic inflammatory disease. ALT-836, in combination with gemcitabine, is also in a Phase I/IIa clinical trial for treating patients with refractory solid tumors.

Visit www.altorbioscience.com for details.

Contact: Altor Bioscience Corporation, Peter Rhode, Ph.D., 954-443-8600